Clinical Trials Directory

Trials / Completed

CompletedNCT03399032

Pharmacokinetics of Caspofungin

Pharmacokinetics of Caspofungin in Critically Ill Patients

Status
Completed
Phase
Study type
Observational
Enrollment
33 (actual)
Sponsor
Medical University of Lublin · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

The objective of this study is to describe the pharmacokinetics of standard doses of caspofungin in critically ill patients.

Detailed description

This is a prospective observational study performed on critically ill patients. Inclusion criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical and surgical patients will be included. Any type of infections will be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes: broad spectrum anti-bacterial antibiotics plus caspofungin (70 mg i.v. on the first day day, and 50 mg i.v. on the consecutive days, once daily. Blood samples (3 mL) will be collected 2, 4, 8,12 and 24 hours after each dose of caspofungin for 3 consecutive days. The standard arterial canula will be used to obtain samples. 30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen. Serum caspofungin concentration will be measured with high performance liquid chromatography. Each patient's hemodynamics parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an antifungal agent will be given as required.

Conditions

Interventions

TypeNameDescription
DRUGCaspofunginEach patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days.

Timeline

Start date
2018-02-05
Primary completion
2018-08-06
Completion
2018-09-03
First posted
2018-01-16
Last updated
2023-11-24

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT03399032. Inclusion in this directory is not an endorsement.